Seattle Genetics to Participate on Panel at RBC Capital Markets Healthcare Conference

Business Wire, Dec 7, 2007

SEATTLE -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will participate in a panel entitled "Delivering on the Promise of Antibody Therapies for Cancer" on Wednesday, December 12, 2007 at 3:30 p.m. Eastern Time as part of the RBC Capital Markets 2007 Healthcare Conference being held at The Westin New York at Times Square Hotel in New York City. The panel discussion will be moderated by Jason Kantor, Ph.D., Senior Biotechnology Analyst at RBC Capital Markets.

A live audio webcast and replay of the panel presentation can be accessed through a link in the News and Investor Information section of Seattle Genetics' website at www.seattlegenetics.com.

About Seattle Genetics

Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide license agreement with Genentech to develop and commercialize SGN-40. Seattle Genetics also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at www.seattlegenetics.com.